ELOXX PHARMACEUTICALS INC (ELOX) Stock Price, Quote, News and Overview
NASDAQ:ELOX - Nasdaq - US29014R2022 - Common Stock - Currency: USD
ELOX Quote, Performance and Key Statistics
3.82
-0.23 (-5.68%)
The current stock price of ELOX is 3.82 USD. In the past month the price decreased by -35.03%. In the past year, price decreased by -40.31%.
ELOX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ELOX
Company Profile
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Company Info
ELOXX PHARMACEUTICALS INC
480 Arsenal Way, Suite 130
Watertown MASSACHUSETTS 02451 US
CEO: Gregory C. Williams
Employees: 18
Company Website: https://www.eloxxpharma.com/
Phone: 17815775300.0
ELOXX PHARMACEUTICALS INC / ELOX FAQ
What is the stock price of ELOXX PHARMACEUTICALS INC today?
The current stock price of ELOX is 3.82 USD. The price decreased by -5.68% in the last trading session.
What is the ticker symbol for ELOXX PHARMACEUTICALS INC stock?
The exchange symbol of ELOXX PHARMACEUTICALS INC is ELOX and it is listed on the Nasdaq exchange.
On which exchange is ELOX stock listed?
ELOX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ELOXX PHARMACEUTICALS INC stock?
7 analysts have analysed ELOX and the average price target is 61.2 USD. This implies a price increase of 1502.09% is expected in the next year compared to the current price of 3.82. Check the ELOXX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ELOXX PHARMACEUTICALS INC worth?
ELOXX PHARMACEUTICALS INC (ELOX) has a market capitalization of 10.70M USD. This makes ELOX a Nano Cap stock.
How many employees does ELOXX PHARMACEUTICALS INC have?
ELOXX PHARMACEUTICALS INC (ELOX) currently has 18 employees.
What are the support and resistance levels for ELOXX PHARMACEUTICALS INC (ELOX) stock?
ELOXX PHARMACEUTICALS INC (ELOX) has a support level at 3.56 and a resistance level at 4.23. Check the full technical report for a detailed analysis of ELOX support and resistance levels.
Should I buy ELOXX PHARMACEUTICALS INC (ELOX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ELOX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ELOX, evaluating the profitability, health, valuation and growth aspects
- ELOXX PHARMACEUTICALS INC (ELOX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ELOXX PHARMACEUTICALS INC (ELOX) Sales and EPS estimates to see what analysts future expectations are.
- ELOXX PHARMACEUTICALS INC (ELOX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ELOXX PHARMACEUTICALS INC (ELOX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ELOXX PHARMACEUTICALS INC (ELOX) Stock Chart to make your own analysis
- ELOXX PHARMACEUTICALS INC (ELOX) Latest news and press-releases to stay up to date.
Does ELOXX PHARMACEUTICALS INC (ELOX) stock pay dividends?
ELOX does not pay a dividend.
When does ELOXX PHARMACEUTICALS INC (ELOX) report earnings?
ELOXX PHARMACEUTICALS INC (ELOX) will report earnings on 2023-11-08, before the market open.
What is the Price/Earnings (PE) ratio of ELOXX PHARMACEUTICALS INC (ELOX)?
ELOXX PHARMACEUTICALS INC (ELOX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.36).
What is the Short Interest ratio of ELOXX PHARMACEUTICALS INC (ELOX) stock?
The outstanding short interest for ELOXX PHARMACEUTICALS INC (ELOX) is 0.08% of its float. Check the ownership tab for more information on the ELOX short interest.
ELOX Technical Analysis
ELOX Financial Highlights
Over the last trailing twelve months ELOX reported a non-GAAP Earnings per Share(EPS) of -11.36. The EPS increased by 43.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -407.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ELOX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to ELOX. The Buy consensus is the average rating of analysts ratings from 7 analysts.